SCHEDULE: Provectus Biopharmaceuticals Shareholder Update
Schedule 13D Amendment
Edward Pershing amends Schedule 13D, reporting 11.61% beneficial ownership of Provectus Biopharmaceuticals common stock, including convertible notes and options.
Summary
- Edward Pershing has filed an amendment (Amendment No. 3) to his Schedule 13D, updating his beneficial ownership of Provectus Biopharmaceuticals, Inc. common stock.
- As of June 30, 2026, Pershing beneficially owns 52,441,275 shares, representing 11.61% of the company's outstanding common stock.
- This ownership includes directly held shares, shares in a retirement plan, shares issuable from stock options, and shares convertible from Series D-1 Convertible Preferred Stock and convertible promissory notes.
- Recent transactions within the last 60 days include the conversion of promissory notes into Series D-1 Convertible Preferred Stock and the purchase of new convertible promissory notes.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it primarily provides an update on beneficial ownership and debt conversions without offering new operational or financial performance data.
Positives
- Edward Pershing maintains a significant beneficial ownership stake of 11.61% in Provectus Biopharmaceuticals, indicating continued investor confidence.
- The filing details the conversion of convertible promissory notes and the purchase of new notes, suggesting ongoing financial activity and potential for future equity conversion.
Negatives
- The filing primarily reports on ownership and conversion of debt instruments, with no specific financial performance metrics or operational updates provided.
- The significant portion of ownership tied to convertible instruments and options introduces potential dilution for existing shareholders upon exercise or conversion.
Risks
- Potential dilution of common stock due to the large number of shares issuable upon conversion of preferred stock and convertible notes.
- The reliance on convertible instruments for a substantial part of the ownership stake may indicate a need for capital or a strategy to defer equity dilution.
Future Outlook
The filing does not contain specific forward-looking statements or guidance from the company. It primarily details current beneficial ownership and the conversion of debt instruments.
Management Comments
- "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."
Industry Context
StockSavvy.ai notes that Schedule 13D filings are common for significant investors acquiring more than 5% of a company's stock. This filing indicates Edward Pershing's substantial and evolving stake in Provectus Biopharmaceuticals, primarily through convertible instruments, which is a typical strategy in the biotechnology sector for managing capital and potential dilution.
Stakeholder Impact
- Shareholders: Potential for dilution if convertible securities are exercised or converted, but also indicates significant investor commitment.
- Creditors: The conversion of promissory notes may reduce outstanding debt for the issuer.
Next Steps
- Continued monitoring of Edward Pershing's beneficial ownership and any further conversions or acquisitions of Provectus Biopharmaceuticals securities.
Key Dates
| Date | Description |
|---|---|
| 2006-2016 | Period of acquisition for other market transactions of common stock. |
| 2018-05-28 | Dates from which secured convertible promissory notes were issued to the Reporting Person. |
| 2024-11-22 | Date of purchase of Series D-1 Convertible Preferred Stock. |
| 2025-12-01 | Date of Amendment No. 2 filing. |
| 2026-02-09 | Date of purchase of Series D-1 Convertible Preferred Stock. |
| 2026-05-07 | Date of convertible promissory note conversion. |
| 2026-05-15 | Date of convertible promissory note conversion. |
| 2026-05-26 | Date of convertible promissory note conversion. |
| 2026-05-28 | Date of purchase of a convertible promissory note. |
| 2026-06-05 | Date of convertible promissory note conversion. |
| 2026-06-26 | Date of conversion of convertible promissory notes plus interest. |
| 2026-06-30 | Date as of which outstanding shares of Common Stock are calculated. |
| 2026-07-22 | Date of signature for Amendment No. 3. |
Keywords
Provectus Biopharmaceuticals, Schedule 13D, Beneficial Ownership, Convertible Notes, Series D-1 Convertible Preferred Stock, Stock Options, Edward Pershing, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.